摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

4-amino-1-[(2R,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-(trifluoromethyl)pyrimidin-2-one

中文名称
——
中文别名
——
英文名称
4-amino-1-[(2R,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-(trifluoromethyl)pyrimidin-2-one
英文别名
——
4-amino-1-[(2R,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-(trifluoromethyl)pyrimidin-2-one化学式
CAS
——
化学式
C10H12F3N3O4
mdl
——
分子量
295.22
InChiKey
XNSPCSMIPDACTB-JXBXZBNISA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    -0.9
  • 重原子数:
    20
  • 可旋转键数:
    2
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.6
  • 拓扑面积:
    108
  • 氢给体数:
    3
  • 氢受体数:
    7

文献信息

  • 2,4-Pyrimidinediamine Compounds and Their Uses
    申请人:Singh Rajinder
    公开号:US20150266828A1
    公开(公告)日:2015-09-24
    The present invention provides 2,4-pyrimidinediamine compounds that inhibit the IgE and/or IgG receptor signaling cascades that lead to the release of chemical mediators, intermediates and methods of synthesizing the compounds and methods of using the compounds in a variety of contexts, including in the treatment and prevention of diseases characterized by, caused by or associated with the release of chemical mediators via degranulation and other processes effected by activation of the IgE and/or IgG receptor signaling cascades.
    本发明提供了抑制IgE和/或IgG受体信号级联反应的2,4-嘧啶二胺化合物,该级联反应导致化学介质的释放,以及合成这些化合物的中介体和方法,以及在多种情况下使用这些化合物的方法,包括在治疗和预防由脱粒和其他由IgE和/或IgG受体信号级联反应激活引起的化学介质释放所表征、引起或相关的疾病。
  • [EN] 2,4-PYRIMIDINEDIAMINE COMPOUNDS FOR USE IN THE TREATMENT OR PREVENTION OF AUTOIMMUNE DISEASES<br/>[FR] COMPOSES 2,4-PYRIMIDINEDIAMINE A UTILISER DANS LE TRAITEMENT OU LA PREVENTION DE MALADIES AUTO-IMMUNES
    申请人:RIGEL PHARMACEUTICALS INC
    公开号:WO2005012294A1
    公开(公告)日:2005-02-10
    The present invention provides methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds, as well as methods of treating, preventing or ameliorating symptoms associated with such diseases. Specific examples of autoimmune diseases that can be treated or prevented with the compounds include rheumatoid arthritis and/or its associated symptoms, systemic lups erythematosis and/or its associated symptoms and multiple sclerosis and/or its associated symptoms.
    本发明提供了使用2,4-嘧啶二胺化合物治疗或预防自身免疫性疾病的方法,以及治疗、预防或改善与这些疾病相关症状的方法。可以使用这些化合物治疗或预防的特定自身免疫性疾病的例子包括类风湿性关节炎及/或其相关症状、系统性红斑狼疮及/或其相关症状以及多发性硬化症及/或其相关症状。
  • COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY
    申请人:Li Hui
    公开号:US20090041786A1
    公开(公告)日:2009-02-12
    The invention encompasses compounds having formula I-V and the compositions and methods using these compounds in the treatment of conditions in which modulation of the JAK pathway or inhibition of JAK kinases, particularly JAK3, may be therapeutically useful.
    这项发明涵盖了具有I-V公式的化合物以及使用这些化合物在治疗需要调节JAK通路或抑制JAK激酶,特别是JAK3的情况下可能具有治疗作用的组合物和方法。
  • 2, 4-pyrimidinediamine compounds and their uses
    申请人:Singh Rajinder
    公开号:US20050038243A1
    公开(公告)日:2005-02-17
    The present invention provides 2,4-pyrimidinediamine compounds that inhibit the IgE and/or IgG receptor signaling cascades that lead to the release of chemical mediators, intermediates and methods of synthesizing the compounds and methods of using the compounds in a variety of contexts, including in the treatment and prevention of diseases characterized by, caused by or associated with the release of chemical mediators via degranulation and other processes effected by activation of the IgE and/or IgG receptor signaling cascades.
    本发明提供了抑制IgE和/或IgG受体信号级联,从而导致化学介质释放的2,4-嘧啶二胺化合物,以及合成这些化合物的中间体和方法,以及在多种情况下使用这些化合物的方法,包括在治疗和预防通过去颗粒化和其他由IgE和/或IgG受体信号级联激活的过程引起或与之相关的化学介质释放所表征的疾病中使用。
  • 2,4-Pyrimidinediamine compounds and their uses
    申请人:——
    公开号:US20040029902A1
    公开(公告)日:2004-02-12
    The present invention provides 2,4-pyrimidinediamine compounds that inhibit the IgE and/or IgG receptor signaling cascades that lead to the release of chemical mediators, intermediates and methods of synthesizing the compounds and methods of using the compounds in a variety of contexts, including in the treatment and prevention of diseases characterized by, caused by or associated with the release of chemical mediators via degranulation and other processes effected by activation of the IgE and/or IgG receptor signaling cascades.
    本发明提供了抑制IgE和/或IgG受体信号级联引起化学介质释放的2,4-嘧啶二胺化合物,以及合成这些化合物的中间体和方法,以及在多种情境下使用这些化合物的方法,包括在治疗和预防由通过激活IgE和/或IgG受体信号级联引起的脱颗粒化和其他过程释放化学介质的疾病中。
查看更多